By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678

Key Statistics

Ownership: Public

Web Site: OncoGenex
Symbol: OGXI

Company News
OncoGenex (OGXI) Reports Financial Results For Third Quarter 2015 11/13/2015 10:13:49 AM
OncoGenex (OGXI) Reports Financial Results For Third Quarter 2015 11/12/2015 4:35:08 PM
OncoGenex (OGXI) To Present At The Stifel 2015 Healthcare Conference 11/6/2015 9:38:16 AM
OncoGenex (OGXI) To Report Third Quarter 2015 Financial Results On November 12, 2015 10/30/2015 6:38:27 AM
OncoGenex (OGXI) Announces European Medicines Agency Support For Phase 3 AFFINITY Trial Protocol Amendment 10/8/2015 6:18:15 AM
OncoGenex (OGXI) Announces Completion Of Patient Enrollment In Borealis-2 Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer 9/30/2015 6:44:57 AM
OncoGenex (OGXI) Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes 9/28/2015 5:59:01 AM
OncoGenex (OGXI) Stock Plummets After Pancreatic Cancer Drug Misses Mark in Phase II Study 9/23/2015 9:42:23 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015 6:26:20 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Second Quarter 2015 Financial Results On August 13, 2015 7/31/2015 11:29:02 AM